Making the right investment decisions in a complex and competitive pharma landscape demands more than just data—it requires deep expertise.
Our Due Diligence services empower organizations across the life sciences sector with a comprehensive view of their target acquisition, uncovering opportunities, highlighting risks, and delivering actionable insights.
Blending our unmatched pharma knowledge with proprietary data and methodologies, we cut through complexity to help our clients invest with confidence.
Due diligence solutions, tailored to each client’s unique needs.
How we can help you.
Assessing market size and dynamics, competitive positioning, and revenue forecasts for informed investment decision-making.
Evaluating technological readiness, scalability, and compliance of your target assets.
Analysing operational capabilities, supply chains, and organizational fit to identify risks and opportunities.
Providing an objective and comprehensive assessment of your company's strengths, risks, and value to build buyer confidence and streamline the transaction process.
Trusted insights. Proven results.
- 300+
- Buy-side, sell-side transactions and PMI supported since 1993
- 100+
- Private Equity and corporate clients served globally
- 75Bn+
- Total market value of transactions
The leading due diligence advisor in the pharma space.
Unmatched pharma knowledge
We bring 30+ years of hands-on experience in the BioPharma industry, ensuring an unparalleled understanding of the unique challenges and opportunities within our client’s markets.
Deal-specific approach
Each acquisition process is unique. Our M&A team works in close collaboration with our customers to ensure each scope addresses the specific needs of the deal.
Customized approach
We tailor our strategies to your specific needs through a collaborative process, ensuring every recommendation aligns with your objectives, operational realities, and long-term goals.
Global expert network
We work in close collaboration with 500+ senior executives, innovators, leading academics, KOL and scientists to better understand what trends will shape Pharma in the future.
Explore related capabilities
Ready to talk?
Get in touch with our experts in due diligence